Gene · 2114
ETS2: ETS proto-oncogene 2, transcription factor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ETS2: ETS proto-oncogene 2, transcription factor. Genes, record 2114. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2114
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P15036 | Protein C-ets-2 | 469 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 7753 | P15036 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14948 | P15036 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7753 | P15036 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14948 | P15036 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14948 | P15036 | Espacenet |
| WO 2024208705 A1 | 2024-10-10 | 4 | P15036 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8982 | P15036 | Espacenet |
| JP 2024123008 A | 2024-09-10 | 8983 | P15036 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14787 | P15036 | Espacenet |
| JP 2024519218 A | 2024-05-09 | 114 | P15036 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,885
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ETS2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 21 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 11 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| P30CA042014 | Cancer Center Support Grant | 9 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 5 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 4 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 4 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,885Source NIH's project files
See all 1,885 nih grantsPapers2,490
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| ETS-2 deficiency impairs brown adipose tissue function through Prdm16 repression. | Metabolism | 2026 | 42800535 | PubTator, text mining | PubMed |
| An Exploratory Single-Cell Analysis Identifies Candidate Shared Molecular Features in Proliferative Diabetic Retinopathy and Parkinson's Disease. | Genes (Basel) | 2026 | 42792898 | PubTator, text mining | PubMed |
| Integrated Structural and Dynamic Analysis Reveals Destabilizing Effects of KRAS Missense Variants Associated with Lung Cancer. | Protein J | 2026 | 42791474 | PubTator, text mining | PubMed |
| Corrigendum to: ΔNp73/ETS2 complex drives glioblastoma pathogenesis-targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. | Neuro Oncol | 2026 | 42710498 | PubTator, text mining | PubMed |
| STAT3-mediated suppression of the pre-induction silencer Ets-2 in activated T helper cells. | Mol Biol Rep | 2026 | 42684610 | PubTator, text mining | PubMed |
| Multi-Omic Analysis of Putative Cellular Senescence-Associated Genes on the Risk of Pan-Cancer. | Mol Carcinog | 2026 | 42669193 | PubTator, text mining | PubMed |
| Magnolol triggers ferroptosis in triple-negative breast cancer through modulation of the ETS2/SLC7A11/GPX4 signaling axis. | Front Pharmacol | 2026 | 42602283 | PubTator, text mining | PubMed |
| Extracellular Vesicles in Cardiovascular Disease: Intercellular Signaling, Liquid Biopsy Biomarkers, and Therapeutic Translation. | Circ Res | 2026 | 42594169 | PubTator, text mining | PubMed |
| From proteome-wide Mendelian randomization and multi-omics integration to functional validation: TGFB3 as a prioritized candidate in gastric adenocarcinoma. | Front Oncol | 2026 | 42518818 | PubTator, text mining | PubMed |
| Is Cellular Senescence a Biological Feature of Long COVID? A Transcriptomic Analysis Across Comparative Postacute Sequelae Phenotypes. | J Infect Dis | 2026 | 42340243 | PubTator, text mining | PubMed |
1 to 10 of 2,490
See all 2,490 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2114
GET https://conductscience.org/api/genes/v1/2114/patents?page=2